Hong Kong, Shanghai, & Florham Park, NJ: Wednesday, March 10, 2021: Hutchison China MediTech Limited (“HUTCHMED”) (Nasdaq/AIM: HCM) announces that following the announcement of the 2020 annual results of HUTCHMED on March 4, 2021, 2,656 American depositary shares (“ADS”) granted under the Long Term Incentive Plan (“LTIP”) on March 15, 2017 to Dr Weiguo Su were vested on March 9, 2021.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
|1||Details of the person discharging managerial responsibilities/person closely associated|
|2||Reason for the notification|
|a)||Position/status||Executive Director and Chief Scientific Officer|
|b)||Initial notification/Amendment||Initial notification|
|3||Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor|
|a)||Name||Hutchison China MediTech Limited|
|4||Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted|
|a)||Description of the financial instrument, type of instrument
|ADS each representing five Ordinary Shares of US$0.10
ADS ISIN: US44842L1035
|b)||Nature of the transaction||Vesting of awards granted on March 15, 2017 under HUTCHMED’s LTIP|
|c)||Price(s) and volume(s)||
|e)||Date of the transaction||2021-03-09|
|f)||Place of the transaction||Outside a trading venue|
HUTCHMED (Nasdaq/AIM: HCM) is an innovative, commercial-stage, biopharmaceutical company committed, over the past twenty years, to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. It has advanced ten cancer drug candidates from discovery into clinical studies around the world and has an extensive commercial infrastructure in its home market of China. For more information, please visit: www.hutch-med.com.
This announcement contains forward-looking statements within the meaning of the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements involve risks and uncertainties. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. For further discussion of these and other risks, see HUTCHMED’s filings with the U.S. Securities and Exchange Commission and on AIM. HUTCHMED undertakes no obligation to update or revise the information contained in this announcement, whether as a result of new information, future events or circumstances or otherwise.
|Mark Lee, Senior Vice President||+852 2121 8200|
|Annie Cheng, Vice President||+1 (973) 567 3786|
|Brad Miles, Solebury Trout||+1 (917) 570 7340 (Mobile)
|Ben Atwell / Alex Shaw, FTI Consulting||+44 20 3727 1030 /
+44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile)
|Joseph Chi Lo, Brunswick||+852 9850 5033 (Mobile)
|Zhou Yi, Brunswick||+852 9783 6894 (Mobile)
|Freddy Crossley / Atholl Tweedie,
Panmure Gordon (UK) Limited
|+44 (20) 7886 2500|